Chronic Obstructive Pulmonary Disease is a chronic respiratory condition characterised by persistent airflow limitation that is usually progressive and associated with an abnormal inflammatory response of the lungs and airways to harmful particles or gases. The term encompasses a spectrum of structural and functional abnormalities, principally involving emphysema, chronic bronchitis and small-airway disease, although not every person has all of these components.
The defining physiological abnormality is obstruction to expiratory airflow that is not fully reversible, reflecting increased airway resistance, loss of elastic recoil, airway narrowing and destruction of supporting lung tissue. The disease affects ventilation, gas exchange and the mechanical work required for breathing, particularly during exertion. Symptoms commonly include persistent breathlessness, chronic cough, sputum production, wheezing, chest tightness and reduced exercise tolerance, but their intensity varies considerably between individuals.
Exacerbations can cause abrupt worsening of respiratory symptoms and may require urgent treatment or hospitalisation. Chronic Obstructive Pulmonary Disease is therefore not simply a persistent cough and should not be equated with any single smoking-related lung abnormality; it is a heterogeneous clinical syndrome defined through the interaction of symptoms, exposure history, structural disease and demonstrable airflow limitation.
The principal established risk factor for Chronic Obstructive Pulmonary Disease is prolonged exposure to tobacco smoke, but the disease has a broader causal framework. Occupational exposure to dusts, fumes, vapours and chemicals, household air pollution, outdoor air pollution, recurrent respiratory insults, impaired lung development and early-life environmental factors can contribute. A genetic deficiency of alpha-1 antitrypsin is an important inherited cause and can produce emphysema at a younger age, particularly in people who smoke.
Risk is influenced by cumulative exposure, duration, susceptibility and the developmental trajectory of the lungs rather than by a single exposure threshold. Chronic Obstructive Pulmonary Disease may develop after years of apparently minor respiratory symptoms, and some people have substantial disease despite relatively modest symptoms because physical activity has gradually been reduced to avoid breathlessness. Conversely, chronic cough or breathlessness does not automatically establish the diagnosis because asthma, heart disease, anaemia, deconditioning and other pulmonary disorders can produce overlapping symptoms. Epidemiologically, Chronic Obstructive Pulmonary Disease is a major cause of chronic illness, disability and premature mortality worldwide, with its burden shaped by smoking prevalence, occupational conditions, air quality, ageing populations and access to prevention and treatment.
The pathophysiology of Chronic Obstructive Pulmonary Disease involves several interacting processes. Chronic airway inflammation can produce mucus hypersecretion, epithelial injury, oedema, remodelling and narrowing of smaller bronchioles. In emphysema, alveolar walls and pulmonary capillary surfaces are destroyed, reducing the area available for gas exchange and diminishing the elastic forces that normally help keep small airways open during expiration.
These changes promote air trapping and hyperinflation, meaning that some air remains in the lungs after exhalation and progressively reduces the available inspiratory capacity. Increased work of breathing can cause respiratory muscle inefficiency and eventually contribute to fatigue. Ventilation and perfusion become uneven, potentially producing low blood oxygen levels and, in advanced disease, carbon dioxide retention. Pulmonary vascular changes may increase resistance in the pulmonary circulation and contribute to pulmonary hypertension and right-sided cardiac strain.
Systemic effects can include skeletal-muscle dysfunction, weight loss, frailty, osteoporosis, cardiovascular disease and reduced exercise capacity. The biological mechanisms are therefore broader than a blocked bronchial tube, and the clinical expression reflects the combined effects of airway inflammation, parenchymal destruction, altered mechanics and systemic consequences.
Diagnosis of Chronic Obstructive Pulmonary Disease requires objective demonstration of persistent airflow obstruction, ordinarily through spirometry performed after appropriate clinical assessment. Spirometry measures volumes and flow rates, especially forced expiratory volume in one second and forced vital capacity, allowing calculation of the ratio between them. A reduced ratio after bronchodilator administration supports persistent airflow obstruction, although interpretation should consider age, reference equations and clinical context.
Assessment also considers symptom burden, frequency and severity of exacerbations, smoking and occupational exposure, exercise limitation, nutritional status and relevant comorbidities. Chest radiography can identify alternative diagnoses or complications, while computed tomography can demonstrate emphysema, airway abnormalities, bronchiectasis or other structural disease when clinically indicated. Oxygen saturation, blood gases, blood tests, electrocardiography and other investigations may be required in advanced or complicated cases.
The historical distinction between chronic bronchitis as a clinical definition based on productive cough and emphysema as an anatomical diagnosis is useful for understanding the disease but does not by itself determine whether someone has Chronic Obstructive Pulmonary Disease. Asthma can coexist with Chronic Obstructive Pulmonary Disease and may require separate consideration because its treatment and physiological pattern can differ.
Management is centred on reducing harmful exposure, controlling symptoms, preventing exacerbations, preserving functional capacity and treating complications and comorbidities. Smoking cessation is particularly important because stopping tobacco exposure reduces ongoing lung injury and improves long-term outcomes regardless of the person's age or established disease. Pharmacological treatment commonly uses inhaled bronchodilators, including long-acting beta2 agonists and long-acting muscarinic antagonists, which reduce airway smooth-muscle constriction and improve airflow.
In selected patients, inhaled corticosteroids may be used, particularly when exacerbation risk and clinical features indicate likely benefit, but they are not universally appropriate and can increase the risk of pneumonia in some circumstances. Correct inhaler technique and adherence are essential because an appropriate drug delivered poorly may provide little benefit. Pulmonary rehabilitation combines structured exercise, education and self-management support and can improve exercise tolerance, symptoms and quality of life.
Vaccination against relevant respiratory pathogens, nutritional support when necessary and management of cardiovascular, skeletal and psychological comorbidities are also important. Long-term oxygen therapy can benefit carefully selected people with chronic severe hypoxaemia, while non-invasive ventilation may have a role in particular forms of chronic or acute respiratory failure.
Acute exacerbations of Chronic Obstructive Pulmonary Disease are episodes in which respiratory symptoms deteriorate beyond normal day-to-day variation and often involve increased breathlessness, cough or sputum production. Viral respiratory infections are common triggers, with bacterial infection, air pollution and other irritants also contributing. Severe exacerbations can produce marked ventilation-perfusion mismatch, respiratory acidosis, hypoxaemia and acute respiratory failure.
Treatment depends on severity and may include intensified inhaled bronchodilators, systemic corticosteroids for appropriate exacerbations, antibiotics when bacterial infection is sufficiently suspected, controlled oxygen administration and ventilatory support. Oxygen is generally administered with a defined target rather than indiscriminately because excessive oxygen can worsen carbon dioxide retention in susceptible people through several physiological mechanisms. Non-invasive ventilation can reduce the need for invasive mechanical ventilation in selected patients with acute hypercapnic respiratory failure.
Prevention of exacerbations is a major treatment objective because repeated episodes can accelerate functional decline, reduce quality of life and increase future exacerbation risk. Written action plans, appropriate inhaler use, vaccination, smoking cessation, pulmonary rehabilitation and personalised maintenance therapy can therefore have consequences extending well beyond symptom control.
The natural history of Chronic Obstructive Pulmonary Disease is highly variable. Some people experience slowly progressive breathlessness with relatively few acute episodes, whereas others have frequent exacerbations and substantial functional impairment. Lung-function decline is influenced by continued exposure to harmful inhalants, age, baseline lung development, genetic susceptibility and exacerbation burden. Advanced disease can lead to chronic respiratory failure, pulmonary hypertension, cor pulmonale, severe exercise limitation and dependence on supplemental oxygen or other supportive measures.
Surgical and interventional options are reserved for selected circumstances; lung-volume-reduction procedures can sometimes benefit people with particular emphysema patterns, while lung transplantation is considered in a small group with advanced disease meeting appropriate criteria. Palliative care can be integrated at any stage when symptom burden is substantial and is not synonymous with abandoning active treatment. Breathlessness management may involve pharmacological and non-pharmacological strategies, psychological support and advance care planning.
Importantly, Chronic Obstructive Pulmonary Disease is preventable or partly preventable in many cases, particularly through tobacco control and occupational and environmental protections, but once established structural lung damage cannot generally be completely reversed. The practical objective is therefore to minimise further injury while maximising respiratory function, independence and quality of life.
Several misconceptions complicate understanding of Chronic Obstructive Pulmonary Disease. It is not exclusively a disease of older smokers, although smoking is a major cause; younger people can develop it because of inherited conditions, substantial environmental exposures or abnormal lung development. It is also not synonymous with emphysema or chronic bronchitis, because those terms describe particular anatomical or clinical components that may occur within the broader disease.
A normal resting oxygen saturation does not exclude clinically significant disease, since exertion can reveal substantial limitation and gas-exchange abnormalities. Similarly, severe symptoms do not always correspond precisely to spirometric impairment because dynamic hyperinflation, cardiovascular disease, muscle conditioning and psychological factors influence perceived breathlessness. Treatment cannot restore destroyed alveoli, but substantial functional improvement is still possible through smoking cessation, inhaled therapy, rehabilitation, vaccination and management of exacerbations.
Modern understanding increasingly treats the condition as heterogeneous rather than as a single uniform phenotype, with airway-predominant disease, emphysema-predominant disease, frequent-exacerbation patterns and overlapping disorders requiring different clinical considerations. Its significance extends beyond pulmonology because it intersects with cardiovascular health, nutrition, physical function, mental wellbeing, occupational medicine and public-health policy.
